Literature DB >> 31668326

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.

Geeta G Sharma1, Diego Cortinovis2, Francesco Agustoni2, Giulia Arosio3, Matteo Villa3, Nicoletta Cordani4, Paolo Bidoli2, William H Bisson5, Fabio Pagni6, Rocco Piazza6, Carlo Gambacorti-Passerini7, Luca Mologni8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31668326     DOI： 10.1016/j.jtho.2019.06.028

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

Review 1.  Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Authors:  Yang Yang; Shuo Li; Yujiao Wang; Yi Zhao; Qiu Li
Journal:  Signal Transduct Target Ther       Date:  2022-09-17

2.  Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase.

Authors:  Luca Mologni; Sébastien Tardy; Alfonso Zambon; Alexandre Orsato; William H Bisson; Monica Ceccon; Michela Viltadi; Joseph D'Attoma; Sara Pannilunghi; Vito Vece; Jerome Bertho; Peter Goekjian; Leonardo Scapozza; Carlo Gambacorti-Passerini
Journal:  ACS Omega       Date:  2022-05-11

Review 3.  Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Authors:  Takamasa Koga; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2022-01-23       Impact factor: 6.716

Review 4.  Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Authors:  Lucy Hare; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

Review 5.  Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.

Authors:  Takafumi Fukui; Motoko Tachihara; Tatsuya Nagano; Kazuyuki Kobayashi
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

6.  Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement.

Authors:  Zhiwei Xiao; Xuewu Huang; Biyuan Xie; Wenzhuan Xie; Mengli Huang; Lizhu Lin
Journal:  Onco Targets Ther       Date:  2020-05-22       Impact factor: 4.147

Review 7.  [Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].

Authors:  Shasha Wang; Yuankai Shi; Xiaohong Han
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.